OA11.06 Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1

• DOI: 10.1016/j.jtho.2024.09.064
• Publication Date: 2024-10-16T02:33:01Z
• Authors: S. Kilickap; A. Sezer; M. Özgüroğlu; M. Gumus; I. Bondarenko; M. Gogishvili; M. Nechaeva; M. Schenker; I. Cicin; H.G. Fuang; Y. Kulyaba; K. Zyuhal; R.-I. Scheusan; A. Baramidze; M.C. Garassino; Y. Li; X. Jia; M. Kaul; J. Perez; F. Seebach; I. Lowy; J.-F. Pouliot; E. Kim; P. Rietschel; H. Magnan
• Keywords: Expression (computer science); Line (geometry)